Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06425614

COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial

Led by University Hospital, Bordeaux · Updated on 2025-06-29

570

Participants Needed

10

Research Sites

82 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Despite significant advances in patient blood management, cardiac surgery remains a surgical procedure at high risk for bleeding. Numerous perioperative blood conservation strategies have been developed for limiting the use of blood products. Among them, the processing of shed blood and residual cardiopulmonary bypass circuit volume with autotransfusion device is routinely used. Conventional centrifugation-based autotransfusion devices actually available only recover red blood cells while platelets and coagulation factors are almost totally lost. Consequently, large amounts of intraoperative cell salvage could significantly alter perioperative haemostasis. The SAME autotransfusion device (i-SEP, France) is a new and innovative filtration-based autotransfusion device able to recover erythrocytes, leukocytes but also platelets. By offering the opportunity to re-infuse to patients their own platelets in addition red blood cells, significantly improve perioperative haemostasis with this new device is expected. The purpose of the COLTRANE trial is to compare the quality of the perioperative haemostasis in cardiac surgical patients for whom intraoperative cell salvage will be performed using either the SAME autotransfusion device or conventional centrifugation-based device. Because allogenic transfusion of blood products as well as surgical re-exploration for excessive bleeding are associated with poor outcomes and prolonged length of stay, the use of filtration-based SAME device by maintaining perioperative haemostasis could improve outcomes and reduce length of stay of high risk patients. The fact that patients receive their own platelets should also limit the risk of allo-immunization and immunomodulation which is recognized as one of the underlying mechanisms of perioperative increased risk of infection.

CONDITIONS

Official Title

COmbined pLaTelet and eRythrocyte AutotransfusioN During Cardiac surgEry (COLTRANE) Trial

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adult patients aged 18 years or older
  • Affiliated or beneficiary of a social security scheme
  • Undergoing on-pump cardiac surgery at high risk for bleeding with autotransfusion indicated
  • Surgery includes primary or redo combined cardiac procedures (2 valves or more, valve(s) and coronary artery bypass grafting(s))
  • Primary or redo ascending aorta surgery
  • Primary or redo isolated coronary artery bypass grafting involving 3 or more grafts using the internal mammary artery
  • Provided free, informed, and written consent signed by participant and investigator
Not Eligible

You will not qualify if you...

  • Preoperative use of P2Y12 receptor inhibitors within specified time frames before surgery
  • Preoperative treatment with active anticoagulant drugs within specified time frames before surgery
  • Presence of sepsis
  • Malignant tumors
  • Immunocompromised patients (on steroids, immunosuppressants, or ongoing cancer treatment)
  • Emergency cardiac surgery
  • Heart transplantation
  • Patients with ventricular assist devices or under implantation
  • Patients with two or more previous sternotomies
  • Surgery requiring circulatory arrest or profound hypothermia below 326C
  • Active infective endocarditis
  • Cardiac surgery for benign or malignant cardiac tumors
  • Known acquired or constitutional coagulopathy requiring specialist management
  • End-stage renal disease
  • Preoperative hemoglobin less than 10 g/dL
  • Preoperative platelet count less than 100 G/L
  • Participation in another ongoing interventional research
  • Pregnant or breastfeeding women
  • Persons under judicial protection
  • Patients deprived of liberty

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 10 locations

1

CHU de Bordeaux, Hôpital cardiologique Haut Lévêque - GH Sud, Service Anesthésie Réanimation Cardiovasculaire

Bordeaux, France, France, 33076

Actively Recruiting

2

HOSPICES CIVILS DE LYON, Hôpital Louis Pradel, Service Anesthésie Réanimation

Bron, France, 69677

Not Yet Recruiting

3

CHU MONTPELLIER, Hôpital Arnaud de Villeneuve, Service Anesthésie Réanimation Arnaud de Villeneuve

Montpellier, France, 34295

Actively Recruiting

4

CHU Nantes, Service Anesthésie Réanimation de chirurgie cardiaque

Nantes, France, 44093

Actively Recruiting

5

Groupe Hospitalier Pitié Salpêtrière, APHP, Service Anesthésie Réanimation chirurgicale

Paris, France, 75651

Not Yet Recruiting

6

Hôpital Bichat-Claude Bernard, APHP, Service Anesthésie Réanimation

Paris, France, 75877

Not Yet Recruiting

7

Hôpital Européen Georges Pompidou, AP-HP, Service Anesthésie Réanimation

Paris, France, 75908

Not Yet Recruiting

8

CHU Rennes, Hôpital Pontchaillou, Service Anesthésie Réanimation 3-Réanimation CTCV

Rennes, France, 35033

Actively Recruiting

9

CHRU STRASBOURG, Nouvel Hôpital Civil, Service Anesthésie Réanimation chirurgicale

Strasbourg, France, 67091

Actively Recruiting

10

CHU Toulouse, Hôpital Rangueil, Service Anesthésie

Toulouse, France, 31400

Not Yet Recruiting

Loading map...

Research Team

A

Alexandre Ouattara, MD, PhD

CONTACT

A

Antoine Beurton, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here